Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
In addition, Pluristem has over 110 pending patent applications.The patents portfolio covers over 30 different innovations across major markets. HAIFA, Israel, April 19, 2017 (GLOBE NEWSWIRE) --...
-
HAIFA, Israel, March 30, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI), (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced advancement in...
-
Yaky Yanay appointed Co-Chief Executive Officer to serve together with Co-Chief Executive Officer Zami AbermanErez Egozi appointed as Chief Financial Officer HAIFA, Israel, March 29, 2017 (GLOBE...
-
HAIFA, Israel, Feb. 13, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today reported financial update...
-
HAIFA, Israel, Jan. 25, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI) announced today that H.C. Wainwright & Co., LLC, the sole book-running manager of its...
-
HAIFA, Israel, Jan. 20, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI) announced today that due to increased demand, it has entered into an amended and restated...
-
HAIFA, Israel, Jan. 19, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) announced today that it has entered into an underwriting agreement with H.C. Wainwright &...
-
PLX-PAD cells could potentially obtain early conditional marketing approval in Europe via the Adaptive Pathways pilot project based on positive interim efficacy data from first 125 patients This...
-
Top line results from the 172-patient trial to be reported in early 2018Data to support Pluristem’s planned Biologics License Application for marketing approval of PLX-PAD in the U.S. and Europe14...
-
HAIFA, Israel, Jan. 10, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that the...